Safety and effectiveness of transoral robotic surgery for oropharyngeal cancer: a pilot study
10.3760/cma.j.issn.1673-0860.2020.02.006
- VernacularTitle: 经口机器人手术治疗口咽癌的安全性及有效性的初步探讨
- Author:
Kai XU
1
;
Lanjun CAI
1
;
Hong CHEN
2
;
Yuanyuan LI
2
;
Zhibin WANG
1
;
Hongyan HUANG
1
;
Hanqi CHU
1
;
Yonghua CUI
1
;
Zheng LIU
1
;
Xiang LU
1
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. Department of Operation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
- Publication Type:Journal Article
- Keywords:
Da Vinci robotic surgery system;
Transoral robotic surgery;
Oropharyngeal cancer;
Minimal invasive surgery
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2020;55(2):109-115
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the indication, safety and effectiveness of transoral robotic surgery (TORS) for oropharyngeal cancer based on our preliminary experience.
Methods:Twelve patients, including six with tonsil cancer, five with tongue base cancer and one with posterior pharyngeal wall cancer, who underwent TORS with Da Vinci Si surgical system from March 2017 to October 2018 at Tongji Hospital of Huazhong University of Science Technology were respectively analyzed. And the surgical time, intraoperative blood loss, postoperative local bleeding, dyspnea, nerve function injury, oral intake time, whether or not to receive chemoradiotherapy were analyzed.
Results:All tumors in the 12 patients were en bloc removed by TORS. Surgical time ranged from 25 to 80 min with an average of 34.2 min. The blood loss ranged from 10 ml to 50 ml with an average of 20.8 ml. The recovery time for oral intake ranged from 1 day to 30 days with an average of 8.4 days. No patient underwent tracheostomy after TORS. Also, no patient manifested with airway obstruction, bleeding or nerve injury symptoms after operation. All 12 patients reached pathologically negative surgical margins. The patients were followed up for 4 to 22 months, with a median of 12 months. All patients who combined with more advanced than T3 stage, or more advanced than N2 stage were recommended to oncologist, then, followed with radiotherapy or chemoradiotherapy if no relevant contradictions occurred. No local recurrence or distant metastasis case was found.
Conclusion:With proper indications, the application of TORS in oropharyngeal cancer is a relatively safe, effective and minimal invasive therapy, which merits more clinical applications.
